brain-cancer
Temozolomide (TMZ) is the standard chemotherapy for glioblastoma (GBM), but its efficacy is limited partly by the P-glycoprotein (ABCB1) efflux transporter at the blood-brain barrier. This systematic review of 4 studies (400+ patients) examined whether ABCB1 gene polymorphisms predict TMZ response…
brain-cancer
Primary central nervous system lymphoma (PCNSL) is treated primarily with high-dose methotrexate (HD-MTX), but new agents presented at ASH 2025 are changing this paradigm. This editorial review summarizes key highlights: BTK inhibitors, immunomodulators, selinexor (an XPO1 inhibitor), and anti-PD-1…
thyroid-cancer
Epithelial-mesenchymal transition (EMT) enables cancer cells to become invasive and metastasize. This study used single-cell RNA sequencing combined with 101 machine learning algorithm combinations to build an EMT-based prognostic model for papillary thyroid carcinoma (PTC).
cervical-cancer
Three-dimensional image-guided brachytherapy (3D-IGBT) for cervical and endometrial cancer requires precise contouring of organs at risk (OARs: bladder, small bowel, rectum, sigmoid) for treatment planning. Manual contouring is time-consuming and variable. This study developed and tested a deep…
prostate-cancer
Meta-analysis of 8 studies (6 RCTs, 2 cohort studies; n=18,456 patients) found ADT + RT significantly improved OS (HR 0.75), PFS (HR 0.41), and PSM (HR 0.52) compared to ADT alone. Subgroup analysis showed greatest benefit in locally advanced or node-positive disease. However, combination…
lung-cancer
A 58-year-old man with lung adenocarcinoma who had received neoadjuvant tislelizumab + carboplatin + docetaxel developed severe concurrent drug-induced liver injury (DILI) and toxic epidermal necrolysis (TEN) 10 days after starting moxifloxacin for pneumonia. Moxifloxacin was the probable causative…
colorectal-cancer
p62 has context-dependent dual roles in CRC: in early inflammation, p62 suppresses tumors by clearing inflammasomes, activating NRF2, and downregulating inflammatory cytokines. But sustained inflammation causes p62 accumulation, reinforcing NRF2, NF-κB, and mTORC1 activation through positive…
pancreatic-cancer
IL-12 is a potent immunostimulatory cytokine with anti-cancer potential, but systemic administration causes severe toxicities (cytokine release syndrome, multi-organ dysfunction). This review covers delivery platforms addressing this: cellular encapsulation, virotherapy, lipid nanocapsules,…
melanoma
Lifileucel received FDA approval for unresectable/metastatic melanoma after PD-1/PD-L1 failure. The C-144-01 study showed median duration of response 36.5 months, median OS 13.9 months, 5-year OS rate 19.7%. However, current TIL therapy requires intensive lymphodepletion and high-dose IL-2,…
colorectal-cancer
A case report of dMMR/MSI-H ascending colon squamous cell carcinoma (primary SCC of colon is extremely rare) treated with 4 cycles of PD-1 blockade monotherapy. The tumor showed significant regression and pathological complete response (pCR) was achieved after surgical resection. Demonstrates that…
melanoma
Bile acids (BAs) are significantly enriched in melanoma and breast cancer tumor microenvironments. BA enrichment drives tumor aerobic glycolysis and immune evasion by activating and stabilizing the FXR-RARα complex, upregulating glycolytic pathways and impairing anti-tumor immunity. BA depletion…
colorectal-cancer
Comprehensive review of Fusobacterium nucleatum (F. nucleatum) as an active co-conspirator in CRC rather than a passenger. F. nucleatum uses virulence factors (Fap2, FadA) for colonization and achieves immune evasion by inhibiting NK/T cells, recruiting MDSCs, driving Th17 polarization, suppressing…